- Home
- DRUG vs FDMT Comparison
DRUG vs FDMT Comparison
Compare DRUG & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRUG
- FDMT
- Stock Information
- Founded
- DRUG 2019
- FDMT 2013
- Country
- DRUG United States
- FDMT United States
- Employees
- DRUG N/A
- FDMT N/A
- Industry
- DRUG Pharmaceuticals and Biotechnology
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- DRUG Health Care
- FDMT Health Care
- Exchange
- DRUG Nasdaq
- FDMT Nasdaq
- Market Cap
- DRUG 345.6M
- FDMT 391.8M
- IPO Year
- DRUG N/A
- FDMT 2020
- Fundamental
- Price
- DRUG $55.20
- FDMT $9.61
- Analyst Decision
- DRUG Strong Buy
- FDMT Strong Buy
- Analyst Count
- DRUG 9
- FDMT 8
- Target Price
- DRUG $81.67
- FDMT $30.63
- AVG Volume (30 Days)
- DRUG 90.8K
- FDMT 688.5K
- Earning Date
- DRUG 08-11-2025
- FDMT 11-12-2025
- Dividend Yield
- DRUG N/A
- FDMT N/A
- EPS Growth
- DRUG N/A
- FDMT N/A
- EPS
- DRUG N/A
- FDMT N/A
- Revenue
- DRUG N/A
- FDMT $33,000.00
- Revenue This Year
- DRUG N/A
- FDMT $9,656.76
- Revenue Next Year
- DRUG N/A
- FDMT N/A
- P/E Ratio
- DRUG N/A
- FDMT N/A
- Revenue Growth
- DRUG N/A
- FDMT N/A
- 52 Week Low
- DRUG $0.94
- FDMT $2.24
- 52 Week High
- DRUG $79.02
- FDMT $9.84
- Technical
- Relative Strength Index (RSI)
- DRUG N/A
- FDMT 63.90
- Support Level
- DRUG N/A
- FDMT $8.11
- Resistance Level
- DRUG N/A
- FDMT $9.03
- Average True Range (ATR)
- DRUG 0.00
- FDMT 0.52
- MACD
- DRUG 0.00
- FDMT -0.01
- Stochastic Oscillator
- DRUG 0.00
- FDMT 76.79
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.